Interruption of BTK Inhibitor Improves Response to SARS-CoV-2 Booster Vaccination in Patients with Chronic Lymphocytic Leukemia
Biomarkers (14)
- ALC Post-Boost - Absolute lymphocyte count after booster SARS-CoV-2 vaccination (phv00531004.v1.p1)
- ALC Post-Initial - Absolute lymphocyte count after primary series SARS-CoV-2 vaccination (phv00531003.v1.p1)
- B2M Post-Boost - Beta-2 microglobulin after booster SARS-CoV-2 vaccination (phv00531020.v1.p1)
- B2M Post-Initial - Beta-2 microglobulin after primary series SARS-CoV-2 vaccination (phv00531019.v1.p1)
- CD4 Post-Boost - CD4 after booster SARS-CoV-2 vaccination (phv00531010.v1.p1)
- CD4 Post-Initial - CD4 after primary series SARS-CoV-2 vaccination (phv00531009.v1.p1)
- IGA Post-Boost - IgA after booster SARS-CoV-2 vaccination (phv00531016.v1.p1)
- IGA Post-Initial - IgA after primary series SARS-CoV-2 vaccination (phv00531015.v1.p1)
- IGG Post-Boost - IgG after booster SARS-CoV-2 vaccination (phv00531014.v1.p1)
- IGG Post-Initial - IgG after primary series SARS-CoV-2 vaccination (phv00531013.v1.p1)
- IGM Post-Boost - IgM after booster SARS-CoV-2 vaccination (phv00531018.v1.p1)
- IGM Post-Initial - IgM after primary series SARS-CoV-2 vaccination (phv00531017.v1.p1)
- Post Boost Titer - Anti-spike antibody titer after booster SARS-CoV-2 vaccination (phv00530997.v1.p1)
- Post Primary Titer - Anti-spike antibody titer after primary series SARS-CoV-2 vaccination (phv00530996.v1.p1)
Demographics (2)
- Age - Age of patient at exam 1 (phv00531000.v1.p1)
- SEX - Biological sex (phv00530994.v1.p1)
Other (19)
- 11q del - Does the patient have an 11q deletion present (phv00531024.v1.p1)
- 13q del - Does the patient have a 13q deletion present (phv00531022.v1.p1)
- 17p del or tp53 mutation - Does the patient have a 17p deletion or TP53 mutation present (phv00531023.v1.p1)
- CD19 Post-Boost - CD19 after booster SARS-CoV-2 vaccination (phv00531006.v1.p1)
- CD19 Post-Initial - CD19 after primary series SARS-CoV-2 vaccination (phv00531005.v1.p1)
- CD3 Post-Boost - CD3 after booster SARS-CoV-2 vaccination (phv00531008.v1.p1)
- CD3 Post-Intial - CD3 after primary series SARS-CoV-2 vaccination (phv00531007.v1.p1)
- CD8 Post-Boost - CD8 after booster SARS-CoV-2 vaccination (phv00531012.v1.p1)
- CD8 Post-Initial - CD8 after primary series SARS-CoV-2 vaccination (phv00531011.v1.p1)
- Complex karyotype - Does the patient have a complex karyotype (phv00531026.v1.p1)
- CONSENT - Consent group as determined by DAC (phv00530993.v1.p1)
- IGHV - IGHV mutational status (phv00531021.v1.p1)
- Number of Prior Tx - The number of treatments prior to current CLL-directed treatment (phv00530999.v1.p1)
- SUBJECT_ID - Subject ID (phv00530995.v1.p1)
- SUBJECT_ID - Subject ID (phv00530992.v1.p1)
- T Cell Response - T-cell response after primary series SARS-CoV-2 vaccination (phv00530998.v1.p1)
- Treatment - Type of treatment that the patient is receiving (phv00531001.v1.p1)
- Trisomy 12 - Does the patient have trisomy 12 (phv00531025.v1.p1)
- Vac Type - The type of vaccine the patient received (phv00531002.v1.p1)